The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Verditek falls on cash shell plans

Wed, 07th Feb 2024 09:29

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Redx Pharma PLC, up 35% at 27.00 pence, 12-month range 19.00p-60.00p. The clinical-stage biotechnology company signs an agreement to sell Kirsten rat sarcoma virus inhibitor program to Jazz Pharmaceuticals PLC. Redx says it will receive USD10 million upfront, with a potential for up to USD870 million in development, regulatory and sales milestone payments in addition to royalties on future net sales. Jazz and Redx will collaborate to advance candidates through IND-enabling studies; Jazz will be responsible for all clinical development, regulatory, manufacturing and commercialization activities.

----------

AIM - LOSERS

----------

Verditek PLC, down 19% at 0.12p, 12-month range 0.080p-1.90p. The producer of lightweight solar panels agrees terms to sell its solar business to a new company, which will be established by the holders of Verditek's secured convertible loan notes for GBP528,340 in notes and GBP50,000 in cash. Upon disposal, Verditek will be regarded as an AIM rule 15 cash shell. Verditek will therefore need to, within six months, make an acquisition or acquisitions which constitute a reverse takeover. It said that it is currently in discussions with "a group of individuals", who it is proposed would come in as a new management team with a view to completing a fundraise of about GBP300,000. The aim would be to conduct a reverse takeover within 6 months of completion of the disposal. "There is no guarantee that this proposal will proceed as it still at an exploratory stage and the company will update the market with more information as soon as it is available," Veritek adds.

----------

Helium One Global Ltd, down 16% at 1.81p, 12-month range 0.19p-10.30p. The primary helium explorer raises GBP4.7 million through a placing of 313.3 million new shares priced at 1.5p each. The placing price represents a 30% discount to the closing price of 2.16p on Tuesday. The proceeds will provide the company with "sufficient" working capital to progress its planning for the next stage of the work programme in Tanzania. Chief Executive Lorna Blaisse says: "The results that we have achieved from the Itumbula West-1 well, flowing helium to surface in such significant concentrations, has confirmed a globally unique helium producing province. By moving quickly and finalising this company led placing early on, we have been able to strengthen our working capital position, which will enable us to fully focus on the next phase of the company's growth."

----------

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
11 May 2015 08:15

Redx Pharma Reaches Pre-Clinical Stage With Oncology Compound

Read more
27 Mar 2015 10:35

REPEAT: Redx Pharma Shares Tick Up After AIM IPO As Sanne Prices Its Offering (ALLIPO)

Read more
27 Mar 2015 10:26

Redx Pharma Shares Tick Up After AIM IPO As Sanne Prices Its Offering

Read more
27 Mar 2015 09:43

Redx Pharma enjoys successful AIM debut

Shares in pharmaceutical development company Redx Pharma traded at a small premium upon the company's debut on the London Stock Exchange. The Liverpool-based group began trading on AIM on Friday, having raised £15m in gross proceeds after placing 17.6m shares at 85p each. The company, which has nom

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.